RxDoctor Payments Data

Andrew Schlein, MD

Internal Medicine · Boynton Beach, FLNPI 1861448946

Payments from drug & device makers

$797in general payments, 2019–2025

Across 43 payments — averaging $18.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$210
  • Amgen$156
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$111
  • Novo Nordisk$85
  • Novartis$67
  • Johnson & Johnson$44
  • plus $125 from 6 others

What the payments were for

  • Food & beverage$797100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$797 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$213,103
Medicare patients
388
Services billed
2,574

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban128$136,335
OzempicSemaglutide75$92,623
XareltoRivaroxaban49$48,656
Repatha SureclickEvolocumab41$44,043
MounjaroTirzepatide36$42,019
FarxigaDapagliflozin Propanediol45$41,705
JardianceEmpagliflozin35$39,608
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$31,759
Tresiba Flextouch U-200Insulin Degludec12$29,167
JanuviaSitagliptin Phosphate37$28,303
MyrbetriqMirabegron39$24,368
Praluent PenAlirocumab29$19,478
EntrestoSacubitril/Valsartan23$18,941
Breo ElliptaFluticasone/Vilanterol20$16,379
Tresiba Flextouch U-100Insulin Degludec26$15,883

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$210$140,623208 claims
Novo NordiskOzempic$85$92,62375 claims
Johnson & JohnsonXarelto$44$48,65649 claims
Lilly USA, LLCMounjaro$15$42,01936 claims
AstraZenecaFarxiga$17$41,70545 claims
NovartisEntresto$67$18,94123 claims
AbbVieLinzess, Synthroid$14$17,81580 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Boynton Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →